tbuckley/cabot-search huggingface dataset:
Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes
Authors: Julia J. Scialla, John Asplin, Mirela Dobre, Alex R. Chang, James Lash, Chi-yuan Hsu, Radhakrishna R. Kallem, L. Lee Hamm, Harold I. Feldman, Jing Chen, Lawrence J. Appel, Cheryl A.M. Anderson, Myles Wolf, Lawrence J. Appel, Harold I. Feldman, Alan S. Go, Jiang He, John W. Kusek, James P. Lash, Akinlolu Ojo, Mahboob Rahman, Raymond R. Townsend
Journal: Kidney International (2016)
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
Authors: E Young, D Noerenberg, L Mansouri, V Ljungström, M Frick, L-A Sutton, S J Blakemore, J Galan-Sousa, K Plevova, P Baliakas, D Rossi, R Clifford, D Roos-Weil, V Navrkalova, B Dörken, C A Schmitt, K E Smedby, G Juliusson, B Giacopelli, J S Blachly, C Belessi, P Panagiotidis, N Chiorazzi, F Davi, A W Langerak, D Oscier, A Schuh, G Gaidano, P Ghia, W Xu, L Fan, O A Bernard, F Nguyen-Khac, L Rassenti, J Li, T J Kipps, K Stamatopoulos, S Pospisilova, T Zenz, C C Oakes, J C Strefford, R Rosenquist, F Damm
Journal: Leukemia (2016)
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
Authors: Sylvia Heink, Nir Yogev, Christoph Garbers, Marina Herwerth, Lilian Aly, Christiane Gasperi, Veronika Husterer, Andrew L Croxford, Katja Möller-Hackbarth, Harald S Bartsch, Karl Sotlar, Stefan Krebs, Tommy Regen, Helmut Blum, Bernhard Hemmer, Thomas Misgeld, Thomas F Wunderlich, Juan Hidalgo, Mohamed Oukka, Stefan Rose-John, Marc Schmidt-Supprian, Ari Waisman, Thomas Korn
Journal: Nature Immunology (2016)
Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Authors: Jeffrey A. Jones, Jennifer Woyach, Farrukh T. Awan, Kami J. Maddocks, Thomas Whitlow, Amy S Ruppert, John C. Byrd
Journal: Blood (2016)
Purification of Anti-HPA-1a Directly from Plasma Using Immobilised Recombinant HPA-1a Enables Determination of Antibody Affinity by Surface Plasmon Resonance Technology in Neonatal Alloimmune Thrombocytopenia.
Authors: Hagop Bessos, Pamela Brown, Gholamreza Anani Sarab, Shirley Gibson, Michael Moss, Robert N Barker, Stanislaw J Urbaniak
Journal: Blood (2008)
Identification of a Unique Autophagy Gene Expression Signature in CD34+ CML Stem/Progenitor Cells That Correlates with Clinical Response to Imatinib Mesylate
Authors: Katharina Rothe, Kevin B.L. Lin, Hanyang Lin, Amy Leung, Donna L. Forrest, Sharon Gorski, Xiaoyan Jiang
Journal: Blood (2012)
Characterizing the morbid genome of ciliopathies
Authors: Ranad Shaheen, Katarzyna Szymanska, Basudha Basu, Nisha Patel, Nour Ewida, Eissa Faqeih, Amal Al Hashem, Nada Derar, Hadeel Alsharif, Mohammed A. Aldahmesh, Anas M. Alazami, Mais Hashem, Niema Ibrahim, Firdous M. Abdulwahab, Rawda Sonbul, Hisham Alkuraya, Maha Alnemer, Saeed Al Tala, Muneera Al-Husain, Heba Morsy, Mohammed Zain Seidahmed, Neama Meriki, Mohammed Al-Owain, Saad AlShahwan, Brahim Tabarki, Mustafa A. Salih, Tariq Faquih, Mohamed El-Kalioby, Marius Ueffing, Karsten Boldt, Clare V. Logan, David A. Parry, Nada Al Tassan, Dorota Monies, Andre Megarbane, Mohamed Abouelhoda, Anason Halees, Colin A. Johnson, Fowzan S. Alkuraya
Journal: Genome biology (2016)

Ciliopathies are clinically diverse disorders of the primary cilium. Remarkable progress has been made in understanding the molecular basis of these genetically heterogeneous conditions; however, our knowledge of their morbid genome, pleiotropy, and variable expressivity remains incomplete.We applied genomic approaches on a large patient cohort of 371 affected individuals from 265 families, with phenotypes that span the entire ciliopathy spectrum. Likely causal mutations in previously described ciliopathy genes were identified in 85% (225/265) of the families, adding 32 novel alleles. Consistent with a fully penetrant model for these genes, we found no significant difference in their "mutation load" beyond the causal variants between our ciliopathy cohort and a control non-ciliopathy cohort. Genomic analysis of our cohort further identified mutations in a novel morbid gene TXNDC15, encoding a thiol isomerase, based on independent loss of function mutations in individuals with a consistent ciliopathy phenotype (Meckel-Gruber syndrome) and a functional effect of its deficiency on ciliary signaling. Our study also highlighted seven novel candidate genes (TRAPPC3, EXOC3L2, FAM98C, C17orf61, LRRCC1, NEK4, and CELSR2) some of which have established links to ciliogenesis. Finally, we show that the morbid genome of ciliopathies encompasses many founder mutations, the combined carrier frequency of which accounts for a high disease burden in the study population.Our study increases our understanding of the morbid genome of ciliopathies. We also provide the strongest evidence, to date, in support of the classical Mendelian inheritance of Bardet-Biedl syndrome and other ciliopathies.
Abstract 1781: G1 phase melanoma cells escape proteasome inhibitor cytotoxicity
Authors: Sheena M. Daignault, David S. Hill, Kimberley A. Beaumont, Andrea Anfosso, Penny E. Lovat, Wolfgang Weninger, Nikolas K. Haass
Journal: Cancer Research (2015)

Abstract Utilising the fluorescent ubiquitination-based cell cycle indicator (FUCCI), which facilitates real-time cell cycle tracking, we have demonstrated in vitro and in vivo that melanomas are composed of differentially cycling tumour cells in a subcompartment-specific distribution. Further, we have shown that targeting the endoplasmic reticulum with fenretinide (synthetic retinoid) or bortezomib (26S proteasome inhibitor) induces cell cycle arrest and apoptosis of metastatic melanoma cells in vitro and in vivo. This study aims to investigate the effect of ER stress-inducing agents on the dynamics of cell division and cell death of individual melanoma cells within the complex tumor microenvironment, and to develop combination strategies that increase the efficacy of ER stress-inducing agents for melanoma therapy. FUCCI-melanoma cells were grown as 3D spheroids and implanted into a collagen matrix to mimic tumor architecture and microenvironment. Utilising the F-XBP1ΔDBD-venus reporter construct, which labels the cytoplasm in response to ER stress, we found that bortezomib induced ER stress, delayed cell cycle progression, and combination with fenretinide increased cell death in 2D and 3D culture. Flow cytometry and confocal microscopy indicated that treatment of FUCCI-melanoma cells with bortezomib induced G2 accumulation in 2D and 3D culture over the course of 24 h. In contrast, by 72 h the majority of cells were in G1 phase. Analysis of 2D and 3D real-time cell cycle imaging movies revealed that bortezomib induced both G1- and G2 arrest, but preferentially killed G2-phase cells. Consequently, pretreatment with temozolomide or fenretinide, leading to G2-arrest, sensitised melanoma cells to bortezomib cytotoxicity. In contrast, pretreatment with MEK inhibitors, leading to G1 arrest, inhibited bortezomib cytotoxicity in all melanoma cells, as did selective BRAF inhibitors in BRAF mutant melanoma cells. Our data suggest that bortezomib combined with fenretinide or temozolamide is a strategy worth exploring for the treatment of BRAF-inhibitor insensitive or resistant melanoma. Importantly, melanoma cells arrested in G1 are protected from bortezomib cytotoxicity, which excludes MAPK pathway inhibitors as combination partners. Citation Format: Sheena M. Daignault, David S. Hill, Kimberley A. Beaumont, Andrea Anfosso, Penny E. Lovat, Wolfgang Weninger, Nikolas K. Haass. G1 phase melanoma cells escape proteasome inhibitor cytotoxicity. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1781. doi:10.1158/1538-7445.AM2015-1781
The Use of Clinical Grade Magnetic Beads to Deplete Immune Suppressive Elements from Autologous Peripheral Blood Hematopoietic Stem Cell Grafts Enhances T Cell Immune Responses.
Authors: Zaid S Al-Kadhimi, Haider Mahdi, Moshrik Abdalamir, Elyse Paul, Voravit Ratanatharathorn, Joseph Uberti, Lawrence G. Lum
Journal: Blood (2008)
Metabolic Analysis of Bone Marrow Mesenchymal Stem Cells and Adipose-Derived Stem Cells Using NMR-Based Metabolomics.
Authors: Rei Ogawa, Juri Fujimura, Keiko Hirakawa, Kyoko Uekusa, Kohtaro Yuta, Hiroshi Mizuno, Youkichi Ohno, Hiko Hyakusoku
Journal: Blood (2006)
ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS
Authors: Ingo K. Mellinghoff, Mehdi Touat, Elizabeth Maher, Macarena DeLaFuente, Timothy F. Cloughesy, Matthias Holdhoff, Gregory Cote, Howard Burris, Filip Janku, Raymond Huang, Robert Young, Benjamin Ellingson, Julia Auer, Hua Liu, Jonathan Hurov, Katherine Yen, Sam Agresta, Eyal Attar, Susan Pandya, Patrick Y. Wen
Journal: Neuro-Oncology (2016)

Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 70% of low grade gliomas and in up to 6% of glioblastomas, and lead to an altered metabolic state associated with increased production of 2-hydroxyglutarate (2-HG) which causes genetic and epigenetic dysregulation leading to oncogenesis. AG120 is a potent oral inhibitor of mutant IDH1 demonstrating suppression of 2-HG in preclinical models and reduced tumor growth in the xenograft TS603 glioma model. In the dose escalation cohorts of this phase 1 study, AG120 was administered daily over a 28 day cycle at doses up to 1200mg in 20 patients with IDH1 mutant glioma who had measurable disease by RANO criteria. AG120 demonstrated a favorable safety profile and preliminary clinical activity with a 35% clinical benefit rate (stable disease or better) at 6 months. The 500mg dose level was expanded in 4 cohorts of solid tumors including progressive non-enhancing glioma (arm 3), and other IDH1 mutated tumors primarily comprised of enhancing glioma (arm 4). Key eligibility: IDH1 mutated disease, ECOG 0–1, no surgery/radiation within 6 months (arm 3). MRI response was assessed every 8 weeks using RANO and LGG-RANO criteria by local and independent review. Exploratory analyses: change in tumor growth rate (FLAIR tumor volume) (Arm 3), and pharmacodynamic evaluations of tissue and serum. As of 14April2016, 25 patients with non-enhancing glioma (arm 3) and 21 patients with contrast enhancing gliomas (arm 4) were enrolled of which 21 (arm 3) and 8 (arm 4) remain on AG120. Median age was 41 and 47 years and median prior regimens were 1 and 2, for non-enhancing and enhancing glioma patients respectively. Frequent adverse events (>10%) regardless of attribution were mostly grade 1/2 headache (4.5% grade 3), nausea, vomiting, fatigue, and diarrhea. Updated safety, response, PK, and exploratory volumetric imaging data will be presented.
Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation
Authors: Chongguang Yang, Tao Luo, Xin Shen, Jie Wu, Mingyu Gan, Peng Xu, Zheyuan Wu, Senlin Lin, Jiyun Tian, Qingyun Liu, ZhengAn Yuan, Jian Mei, Kathryn DeRiemer, Qian Gao
Journal: The Lancet Infectious Diseases (2016)
Casein kinase 2 controls the survival of normal thymic and leukemic γδ T cells via promotion of AKT signaling
Authors: S T Ribeiro, M Tesio, J C Ribot, E Macintyre, J T Barata, B Silva-Santos
Journal: Leukemia (2016)

The thymus is the major site for normal and leukemic T-cell development. The dissection of the molecular determinants of T-cell survival and differentiation is paramount for the manipulation of healthy or transformed T cells in cancer (immuno)therapy. Casein kinase 2 (CK2) is a serine/threonine protein kinase whose anti-apoptotic functions have been described in various hematological and solid tumors. Here we disclose an unanticipated role of CK2 in healthy human thymocytes that is selective to the γδ T-cell lineage. γδ thymocytes display higher (and T-cell receptor inducible) CK2 activity than their αβ counterparts, and are strikingly sensitive to death upon CK2 inhibition. Mechanistically, we show that CK2 regulates the pro-survival AKT signaling pathway in γδ thymocytes and, importantly, also in γδ T-cell acute lymphoblastic leukemia (T-ALL) cells. When compared with healthy thymocytes or leukemic αβ T cells, γδ T-ALL cells show upregulated CK2 activity, potentiated by CD27 costimulation, and enhanced apoptosis upon CK2 blockade using the chemical inhibitor CX-4945. Critically, this results in inhibition of tumor growth in a xenograft model of human γδ T-ALL. These data identify CK2 as a novel survival determinant of both healthy and leukemic γδ T cells, and may thus greatly impact their therapeutic manipulation.
Mesh—Is Less More?
Authors: Bhumy A. Davé, Anne-Marie Boller
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Acute Myeloid Leukemia or Myelodysplastic Syndromes and All-Cause Mortality in Randomized Controlled Trials of Cancer Patients Receiving Chemotherapy with or without Granulocyte Colony-Stimulating Factor: A Systematic Review and Meta-Analysis.
Authors: Gary H. Lyman, Jeffrey Crawford, Eva Culakova, Marek S. Poniewierski, Debra Wolff, Nicole M. Kuderer, David C. Dale
Journal: Blood (2009)
Let’s not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!
Authors: Kenneth F Baker, Arthur G Pratt, Ben Thompson, John D Isaacs
Journal: Annals of the Rheumatic Diseases (2016)

We were interested to read Dr Boer’s recent eLetter,1 in which he outlines the merits of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2011 consensus remission criteria in rheumatoid arthritis (RA),2 and proposes that this definition equates with absence of disease.

The 2011 ACR/EULAR remission criteria do indeed hold several benefits over composite index-based remission definitions such as the disease activity score in 28 joints (DAS28). The ACR/EULAR criteria are widely regarded to be more stringent at defining remission than DAS28-erythrocyte sedimentation rate (ESR) <2.6, supported by a stronger correlation with lower rates of radiographic progression in the ACR/EULAR definition.2 Furthermore, the ACR/EULAR criteria were developed by consensus agreement among a …
A Plant Triterpenoid Avicin D Stimulates Adipocytic Differentiation of Bone Marrow Stromal Cells and Promotes Their Pro-Survival Effects On Acute Monoblastic Leukemia Cells
Authors: Yoko Tabe, Linhua Jin, Saiko Kazuno, Tsutomu Fujimura, Hiromichi Matsushita, Takashi Ueno, Michael Andreeff, Jordan U. Gutterman, Marina Konopleva
Journal: Blood (2012)
Risk Factors Analysis of Outcomes of Related Cord Blood Transplantation in Children with Hematological Malignancies.
Authors: Pierre Teira, Vanderson Rocha, Franco Locatelli, Ricardo Pasquini, Gerard Socie, Yves Bertrand, Franca Fagioli, Chiara Messina, Manuel Abecasis, Michel Gerard, Ulla Pihkala, Irina Ionescu, Federico Garnier, Eliane Gluckman
Journal: Blood (2006)
Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells
Authors: Rakesh Verma, Till Strowig, Rituparna Das, Srinivas Koduru, Anja Hafemann, Stephanie Hopf, Mehmet H. Kocoglu, Chiara Borsotti, Lin Zhang, Andrew R Branagan, Elizabeth Eynon, Markus Manz, Richard Flavell, Madhav V Dhodapkar
Journal: Blood (2015)
Bone Marrow T Cells Are More Effective Than Peripheral T Cells in Inducing Chimeric Conversion Following MHC-Mismatched Nonmyeloablative Bone Marrow Transplantation
Authors: Seok-Goo Cho, Hyunsil Park, Min Jung Park, Ho-Youn Kim, Jong-Wook Lee, Woo-Sung Min
Journal: Blood (2008)
Allogeneic or Autologous Stem Cell Transplantation (SCT) for the Treatment of Pediatric Patients with Non-Hodgkins Lymphoma (NHL).
Authors: Rosanna Ricafort, Tanya Trippett, Nancy A. Kernan, Trudy N. Small, Susan Prockop, Andromachi Scaradavou, Anna Keating, Richard J. O’Reilly, Farid Boulad
Journal: Blood (2005)
Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Authors: Andrei Shustov, Barbara Pro, Christian Gisselbrecht, Leslie Popplewell, Nancy L. Bartlett, Mary Jo Lechowicz, Jasmine M. Zain, Faith Young, Richard R. Furman, Steven M. Fruchtman, Steven M Horwitz, Owen A. O'Connor
Journal: Blood (2010)
Preserving fertility in girls and young women with cancer
Authors: Richard A Anderson, Melanie C Davies
Journal: BMJ (2016)

Awareness of and access to services remains poor in the UK

Advances in the treatment of cancer in children and young adults have meant that more survivors are living with the long term consequences of treatment.1 Loss of fertility is a big concern,2 and infertility is common after high dose chemotherapy and pelvic irradiation.3 Fertility preservation has been available to men for many years; semen cryostorage before treatment yields viable sperm for later in vitro fertilisation (IVF). Women, however, require more complex and invasive procedures.4 This aspect of the holistic care of young people with cancer has been highlighted by the recent announcement of the first baby born in the UK to a woman who had regrafting of ovarian tissue that was cryopreserved 10 years earlier.5

The options for women facing loss of fertility from treatment for cancer or other therapies include cryopreservation of oocytes, embryos, or, more experimentally, ovarian tissue. Embryo freezing has been used successfully for three decades. Oocyte freezing is technically more …
CD20 Expression Is Associated with Higher Risk of Early Relapse at 1 Year Following Chemotherapy Treatment for Adolescent and Adult Acute Lymphoblastic Leukemia Patients
Authors: Feras Alfraih, Abdul Mannnan, Dennis Dong Hwan Kim, Ghuzayel Aldawsari, Fahad Z. Alsharif, Hazza A Alzahrani, Said Y Mohamed, Walid Rasheed, Amr Hanbali, Syed Osman Ahmed, Marwan Shaheen, Fahad Al Mohareb, Mahmoud Aljurf, Naeem A. Chaudhri
Journal: Blood (2015)
Influence of the Variable Number of Tandem Repeat and Kozak Sequence Polymorphisms in Platelet GPIbα and the C807t α2 Integrin Polymorphism in Type 1 von Willebrand Disease.
Authors: Margaret L. Rand, Iris Hedlund-Treutiger, Christine Hough, Victor S. Blanchette, David Lillicrap
Journal: Blood (2004)
Primary Mediastinal Large B-Cell Lymphoma: Long Term Results with an Alternating Chemotherapy Regimen Based on High-Dose Methotrexate.
Authors: Thomas J. Fietz, F. Fiedler, Astrid Franke, Mathias Freund, Dietger W. Niederwieser, Eckhard Thiel, Wolfgang U. Knauf
Journal: Blood (2004)
PWE-041 Ibd – the unseen effects of chronic illness: Abstract PWE-041 Table 1
Authors: FM Beaton, JC Paterson, E Robinson, JA Todd, N Reynolds, C Mowat, M Groome
Journal: Gut (2015)

<h3>Introduction</h3> Inflammatory Bowel Disease (IBD), incorporating Crohns Disease (CD) and Ulcerative colits (UC), is a chronic condition that can cause significant gastrointestinal morbidity. Alongside the anticipated gastrointestinal symptoms, patients with chronic illness may experience issues with low mood, relationships, employment and education opportunities, and may miss significant time off work. In this pilot project, we sought to record the additional morbidity experienced by a typical cohort of IBD patients. <h3>Method</h3> Over a 3-week period 100 consecutive patients attending an IBD clinic in a tertiary teaching hospital were surveyed by questionnaire. Questions addressed demographics, impact of IBD on lifestyle, mood, relationships, and education/employment. Disease activity over the preceding 12 months was noted. Remission was defined by Physician Global Assessment, plus the absence of steroid use within the last 12 months, plus normal CRP. Data were analysed according to disease activity. <h3>Results</h3> A total of 100 questionnaires were completed by 44 males (aged 15–80) and 56 females (aged 19–81). 63 patients had CD (M:F 28:35), 37 had UC (M:F 16:21). 56% of patients had clinically active disease and 44% were in clinical remission. There was no significant difference in ages between those patients with active or inactive disease. The majority in both groups had felt depressed at times; 81% of those patients with active disease and 68% with inactive disease. Table 1shows morbidity by disease activity. 75% from each group reported IBD has impacted on their lifestyle in the preceding 12 months, and over 60% from each group reported IBD had restricted their activities. In terms of employment, 3% were unemployed with active disease and 16% in the inactive group with the rest being in some form of employment, full time education or retired. Only 32% of those with active disease and 31% in remission reported no loss of days at work in the preceding 12 months. 16% of those with active disease and interesting 36% of those in remission reported the loss of greater than 2 weeks at work due to their IBD in the preceding 12 months. <h3>Conclusion</h3> We have demonstrated that, irrespective of disease activity, IBD has a significant impact on the physical and psychological health, and employment record of the patients surveyed. Patients’ psychological health is important and should be actively addressed when reviewing patients with IBD in outpatient clinics. <h3>Disclosure of interest</h3> None Declared.
Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)
Authors: Hady Ghanem, Hagop M. Kantarjian, Farhad Ravandi, Jorge E. Cortes, Naveen Pemmaraju, Stefan Faderl, Sara E Dellasala, Susan M. O'Brien, Jan A. Burger, Gautam Borthakur, Tapan M. Kadia, Alfonso Quintás-Cardama, Mark Brandt, Sherry A. Pierce, Guillermo Garcia-Manero, Elias J. Jabbour
Journal: Blood (2012)
Sickle Cell Mice with Hypoxia-Reoxygenation Have Oxidative and Inflammatory Liver Injury - toward a New Experimental Model for Vaso- Occlusive Injury
Authors: Lewis L. Hsu, Sruti Shiva, Caroline Mendelsohn, Michael R Hsu, Audrey C Noguchi, Laurel Mendelsohn, Mark Gladwin
Journal: Blood (2008)
Correlation of Erythropoietin Stimulating Agents (ESAs) with the Post-Therapy Micro-Vessel Density (MVD) in Newly Diagnosed Myeloma Patients: a Possible Mechanism of ESAs Association with Reduced Survival Rates.
Authors: Eirini Katodritou, Evangelos Terpos, Vassiliki Kaloutsi, Evgenia Verrou, Vassiliki Gastari, Maria Varthaliti, Christina Hadjiaggelidou, Evgenia Panousi, Sofia Georgiadou, Constantinos Hatjileontis, Nicos Konstantinou, Konstantinos Zervas
Journal: Blood (2009)
No Panacea: Next-Gen Sequencing Will Not Mitigate Adoptees’ Lack of Genetic Family Health History
Authors: Stephanie M. Fullerton
Journal: The American Journal of Bioethics (2016)

There are currently more than 2 million adopted children under the age of 18 years living in the United States (Kreider and Lofquist 2010) and many other adults who were themselves adopted as child...